

Pablo Barreiro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4224645/pablo-barreiro-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229
papers

6,488
citations

45
h-index

66
g-index

251
ext. papers

7,373
ext. citations

4.4
avg, IF

5.52
L-index

| # | Paper | IF | Citations |
|-----|--|-------|-----------|
| 229 | A pilot study for the evaluation of an interferon-gamma release assay (IGRA) to measure T-cell immune responses after SARS-CoV-2 infection or vaccination in a unique cloistered cohort.. <i>Journal of Clinical Microbiology</i> , 2022 , jcm0219921 | 9.7 | 2 |
| 228 | Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.. <i>AIDS Reviews</i> , 2022 , | 1.5 | 5 |
| 227 | Use of antibiotics in respiratory viral infections.. <i>Internal and Emergency Medicine</i> , 2022 , 1 | 3.7 | |
| 226 | Infection and infectivity: Utility of rapid antigen tests for the diagnosis of COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021 , 34 Suppl 1, 46-48 | 1.6 | 1 |
| 225 | Approach to COVID-19 pandemic management in Madrid. Chronic of a year. <i>Revista Espanola De Quimioterapia</i> , 2021 , 34 Suppl 1, 76-80 | 1.6 | |
| 224 | Trends in hospitalizations and deaths in HIV-Infected patients in Spain over two decades. <i>Aids</i> , 2021 , 36, | 3.5 | 1 |
| 223 | Integral management of COVID-19 in Madrid: Turning things around during the second wave. <i>Lancet Regional Health - Europe, The</i> , 2021 , 2, 100039 | | 8 |
| 222 | Temporary hospitals in times of the COVID pandemic. An example and a practical view. <i>Revista Espanola De Quimioterapia</i> , 2021 , 34, 280-288 | 1.6 | 13 |
| 221 | Main differences between the first and second waves of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021 , 105, 374-376 | 10.5 | 44 |
| 220 | Integral management of COVID-19 in Madrid: Turning things around during the second wave-AuthorsReply. <i>Lancet Regional Health - Europe, The</i> , 2021 , 3, 100076 | | 2 |
| 219 | Social Restrictions versus Testing Campaigns in the COVID-19 Crisis: A Predictive Model Based on the Spanish Case. <i>Viruses</i> , 2021 , 13, | 6.2 | 1 |
| 218 | The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS study. <i>Age and Ageing</i> , 2021 , 50, 1038-1047 | 3.047 | 10 |
| 217 | Third wave of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021 , 107, 212-214 | 10.5 | 16 |
| 216 | SARS-CoV-2 B.1.1.7 Variant Outbreak in a Fully Vaccinated Nursing Home-Madrid, June 2021. <i>Journal of the American Medical Directors Association</i> , 2021 , 22, 2266-2268 | 5.9 | 1 |
| 215 | Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. <i>International Journal of Infectious Diseases</i> , 2021 , 112, 81-88 | 10.5 | 4 |
| 214 | Hospital admissions in individuals with HTLV-1 infection in Spain. <i>Aids</i> , 2020 , 34, 1019-1027 | 3.5 | 6 |
| 213 | A case of acute generalized exanthematous pustulosis caused by exposure to Atovaquone/proguanil. <i>Journal of Travel Medicine</i> , 2020 , 27, | 12.9 | 1 |

| | | | |
|-----|--|-------|----|
| 212 | Rapid antigen Testing and Mask Wearing While Waiting for COVID-19 Vaccines. <i>AIDS Reviews</i> , 2020 , 22, 168-172 | 1.5 | 2 |
| 211 | Unveiling Long COVID-19 Disease. <i>AIDS Reviews</i> , 2020 , 22, 227-228 | 1.5 | 5 |
| 210 | Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings. <i>Revista Espanola De Quimioterapia</i> , 2020 , 33, 466-484 | 1.6 | 31 |
| 209 | Coronavirus and other airborne agents with pandemic potential. <i>Current Opinion in Environmental Science and Health</i> , 2020 , 17, 41-48 | 8.1 | 2 |
| 208 | Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit. <i>Travel Medicine and Infectious Disease</i> , 2020 , 33, 101543 | 8.4 | 3 |
| 207 | Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa320 | 1 | |
| 206 | Long-acting antiretroviral therapy. <i>Nature Materials</i> , 2020 , 19, 826-827 | 27 | 8 |
| 205 | Advances in hepatitis B therapeutics. <i>Therapeutic Advances in Infectious Disease</i> , 2020 , 7, 2049936120965027 | 5.027 | 12 |
| 204 | COVID-19 Comes 40 Years After AIDS - Any Lesson?. <i>AIDS Reviews</i> , 2020 , 22, 63-77 | 1.5 | 2 |
| 203 | Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppressors and failure of antiretrovirals. <i>Therapeutic Advances in Infectious Disease</i> , 2019 , 6, 2049936119868028 | 2.8 | 14 |
| 202 | Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz036 | 1 | 5 |
| 201 | HTLV testing of solid organ transplant donors. <i>Clinical Transplantation</i> , 2019 , 33, e13670 | 3.8 | 5 |
| 200 | Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1357-1362 | 5.1 | 12 |
| 199 | Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 507-517 | 3.8 | 29 |
| 198 | AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities. <i>Viruses</i> , 2018 , 10, | 6.2 | 4 |
| 197 | Decline and changing profile of hepatitis delta among injection drug users in Spain. <i>Antiviral Therapy</i> , 2018 , 23, 87-90 | 1.6 | 5 |
| 196 | HIV type 2 epidemic in Spain: challenges and missing opportunities. <i>Aids</i> , 2017 , 31, 1353-1364 | 3.5 | 15 |
| 195 | Malaria and severe anemia over eight years at Gambo Rural Hospital, southern Ethiopia. <i>Pathogens and Global Health</i> , 2017 , 111, 195-199 | 3.1 | 5 |

| | | | |
|-----|--|------|----|
| 194 | Human T-lymphotropic virus type 1 infection and disease in Spain. <i>Aids</i> , 2017 , 31, 1653-1663 | 3.5 | 20 |
| 193 | Hepatitis delta and HIV infection. <i>Aids</i> , 2017 , 31, 875-884 | 3.5 | 21 |
| 192 | Dual antiretroviral therapy for HIV infection. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 923-932 | 4.1 | 35 |
| 191 | New antivirals for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 843-851 | 5.9 | 28 |
| 190 | Treatment of hepatitis C with new fixed dose combinations. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1235-1242 | 4 | 17 |
| 189 | Diagnosis of cutaneous anthrax in resource-poor settings in West Arsi Province, Ethiopia. <i>Annals of Agricultural and Environmental Medicine</i> , 2017 , 24, 712-715 | 1.4 | 5 |
| 188 | Need to Face Liver Cirrhosis after HCV Cure with Antivirals. <i>EBioMedicine</i> , 2017 , 24, 24-25 | 8.8 | 3 |
| 187 | Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 1015-1022 | 5.5 | 10 |
| 186 | Is Ribavirin Teratogenic in Humans? No Evidence So Far. <i>Drug Safety</i> , 2017 , 40, 1163-1165 | 5.1 | 0 |
| 185 | Drug interactions in HIV-infected patients treated for hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 807-816 | 5.5 | 15 |
| 184 | High serum HCV RNA in chronic hepatitis C patients coinfecting with HIV despite successful antiretroviral therapy. <i>Antiviral Therapy</i> , 2016 , 21, 489-494 | 1.6 | 6 |
| 183 | Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. <i>Liver International</i> , 2016 , 36, 763 | 7.9 | 5 |
| 182 | Prevalence of positive HIV, HBV, HCV and treponemal tests in blood donors in a rural hospital in southern Ethiopia. <i>Journal of Clinical Virology</i> , 2016 , 77, 60-2 | 14.5 | 4 |
| 181 | Delta hepatitis: new approaches to therapy. <i>Future Virology</i> , 2016 , 11, 197-205 | 2.4 | |
| 180 | New hepatitis C therapies for special patient populations. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 217-29 | 4 | 21 |
| 179 | Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. <i>Antiviral Therapy</i> , 2016 , 21, 91-2 | 1.6 | 17 |
| 178 | Hepatitis C cure with antiviral therapy--benefits beyond the liver. <i>Antiviral Therapy</i> , 2016 , 21, 1-8 | 1.6 | 30 |
| 177 | Tenofovir for Hepatitis Delta. <i>Hepatology</i> , 2016 , 63, 1395-6 | 11.2 | 6 |

| | | | |
|-----|--|------|----|
| 176 | Hypoglycemia in a diabetic patient during hepatitis C therapy. <i>Hepatology</i> , 2016 , 63, 2065-6 | 11.2 | 14 |
| 175 | Prevention and management of treatment failure to new oral hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1215-23 | 4 | 42 |
| 174 | Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 47-52 | 3.4 | 51 |
| 173 | Emerging challenges in managing hepatitis B in HIV patients. <i>Current HIV/AIDS Reports</i> , 2015 , 12, 344-52 | 5.9 | 19 |
| 172 | Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1421-34 | 4.1 | 13 |
| 171 | Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2015 , 71, 63-6 | 14.5 | 8 |
| 170 | Gene therapy for HIV infection. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 319-27 | 5.4 | 7 |
| 169 | Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients. <i>Antiviral Therapy</i> , 2015 , 20, 329-34 | 1.6 | 13 |
| 168 | Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2015 , 20, 65-72 | 1.6 | 15 |
| 167 | Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 179-86 | 4 | 5 |
| 166 | Drug interactions with new hepatitis C oral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 333-41 | 5.5 | 44 |
| 165 | Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1549-53 | 11.6 | 60 |
| 164 | Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014 , 68, 372-7 | 18.9 | 3 |
| 163 | Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1051-7 | 4 | 8 |
| 162 | Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014 , 105, 1-7 | 10.8 | 23 |
| 161 | Pharmacogenetics of antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1119-30 | 5.5 | 10 |
| 160 | Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014 , 19, 799-803 | 1.6 | 8 |
| 159 | Very late HCV relapse following triple therapy for hepatitis C. <i>Antiviral Therapy</i> , 2014 , 19, 723-4 | 1.6 | 4 |

| | | | |
|-----|--|------|----|
| 158 | Management and treatment of chronic hepatitis B in HIV-positive patients. <i>Annals of Medicine</i> , 2014 , 46, 290-6 | 1.5 | 9 |
| 157 | Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 475-9 | 3.4 | 15 |
| 156 | Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. <i>Genes and Immunity</i> , 2014 , 15, 16-24 | 4.4 | 15 |
| 155 | Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. <i>Aids</i> , 2014 , 28, 2389-94 | 3.5 | 39 |
| 154 | Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. <i>Aids</i> , 2014 , 28, 1473-8 | 3.5 | 23 |
| 153 | Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy. <i>Antiviral Therapy</i> , 2014 , 19, 287-92 | 1.6 | 5 |
| 152 | Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1161-70 | 4 | 45 |
| 151 | Update on HIV/HCV coinfection. <i>Current HIV/AIDS Reports</i> , 2013 , 10, 226-34 | 5.9 | 42 |
| 150 | Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013 , 32, 1427-35 | 5.3 | 9 |
| 149 | Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2013 , 12, 269-275 | | 3 |
| 148 | Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013 , 67, 59-64 | 18.9 | 9 |
| 147 | Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1117-22 | 11.6 | 19 |
| 146 | Hepatitis B in HIV-infected patients. <i>Clinics in Liver Disease</i> , 2013 , 17, 489-501 | 4.6 | 21 |
| 145 | Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. <i>Journal of Clinical Virology</i> , 2013 , 58, 391-5 | 14.5 | 6 |
| 144 | Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 697-707 | 4.1 | 18 |
| 143 | The changing face of hepatitis C in the new era of direct-acting antivirals. <i>Antiviral Research</i> , 2013 , 97, 36-40 | 10.8 | 21 |
| 142 | Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. <i>Aids</i> , 2013 , 27, 2219-24 | 3.5 | 14 |
| 141 | Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfecting with HIV and hepatitis viruses. <i>Journal of Infectious Diseases</i> , 2013 , 207, 1379-88 | 7 | 35 |

| | | | |
|-----|---|------|----|
| 140 | Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver. <i>Clinical Infectious Diseases</i> , 2013 , 56, 560-6 | 11.6 | 17 |
| 139 | Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. <i>Clinical Infectious Diseases</i> , 2013 , 57, 465-8 | 11.6 | 76 |
| 138 | Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. <i>Liver International</i> , 2013 , 33, 1357-62 | 7.9 | 36 |
| 137 | Pharmacokinetics of new oral hepatitis C antiviral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 5-16 | 5.5 | 13 |
| 136 | Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfecting patients. <i>Aids</i> , 2013 , 27, 1187-8 | 3.5 | 20 |
| 135 | Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013 , 27, 2715-24 | 3.5 | 7 |
| 134 | Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. <i>Aids</i> , 2013 , 27, 1129-34 | 3.5 | 21 |
| 133 | Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013 , 18, 709-15 | 1.6 | 12 |
| 132 | Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C. <i>Antiviral Therapy</i> , 2013 , 18, 1033-5 | 1.6 | 10 |
| 131 | The changing epidemiology of liver disease in HIV patients. <i>AIDS Reviews</i> , 2013 , 15, 25-31 | 1.5 | 32 |
| 130 | Treatment failure with new hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 313-23 | 4 | 27 |
| 129 | Different impact of IL28B polymorphisms on response to peginterferon- α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012 , 55, 58-61 | 14.5 | 12 |
| 128 | Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era. <i>Infectious Disease Clinics of North America</i> , 2012 , 26, 931-48 | 6.5 | 7 |
| 127 | Predicted effect of direct acting antivirals in the current HIV-HCV-coinfecting population in Spain. <i>Antiviral Therapy</i> , 2012 , 17, 571-5 | 1.6 | 13 |
| 126 | Management and treatment of chronic hepatitis C in HIV patients. <i>Seminars in Liver Disease</i> , 2012 , 32, 138-46 | 7.3 | 21 |
| 125 | Pharmacogenetics of hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 523-9 | 5.1 | 26 |
| 124 | Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon- α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. <i>Journal of Infectious Diseases</i> , 2012 , 206, 961-8 | 7 | 18 |
| 123 | Differences in virological response to peginterferon- α plus ribavirin in HIV-positive patients coinfecting with HCV subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, 117-23 | 3.1 | 12 |

| | | | |
|-----|---|------|----|
| 122 | Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. <i>Antiviral Therapy</i> , 2012 , 17, 921-6 | 1.6 | 42 |
| 121 | Antiretroviral drugs for pre-exposure prophylaxis of HIV infection. <i>AIDS Reviews</i> , 2012 , 14, 54-61 | 1.5 | 10 |
| 120 | Psychopharmacological treatments in HIV patients under antiretroviral therapy. <i>AIDS Reviews</i> , 2012 , 14, 101-11 | 1.5 | 5 |
| 119 | Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/Hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011 , 25, 1131-3 | 3.5 | 20 |
| 118 | New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. <i>Aids</i> , 2011 , 25, 1013-4 | 3.4 | 10 |
| 117 | Elevated TGF- β levels might protect HCV/ HIV-coinfected patients from liver fibrosis. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 70-6 | 4.6 | 20 |
| 116 | Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 11-6 | 3.4 | 56 |
| 115 | Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 325-30 | 3.4 | 20 |
| 114 | Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 542-8 | 3.4 | 3 |
| 113 | Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011 , 12, 487-93 | 2.7 | 15 |
| 112 | HCV and HIV Coinfection. <i>Current Hepatitis Reports</i> , 2011 , 10, 52-61 | | 1 |
| 111 | Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2011 , 203, 1629-36 | 7 | 55 |
| 110 | Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1291-5 | 11.6 | 13 |
| 109 | Directly acting antivirals against hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1673-86 | 3.6 | 75 |
| 108 | Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. <i>AIDS Reviews</i> , 2011 , 13, 171-9 | 1.5 | 17 |
| 107 | Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 866-71 | 3.4 | 1 |
| 106 | Long-term treatment of patients with HIV-1: the role of atazanavir. <i>HIV/AIDS - Research and Palliative Care</i> , 2010 , 2, 157-66 | 1.2 | |
| 105 | Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfecting with hepatitis C virus and HIV. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1209-16 | 11.6 | 51 |

| | | | |
|-----|---|------|-----|
| 104 | Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , 2010 , 202, 1185-91 | 7 | 31 |
| 103 | Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 419-24 | 1.6 | 5 |
| 102 | Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1647-9 | 5.9 | 18 |
| 101 | Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. <i>HIV Clinical Trials</i> , 2010 , 11, 197-204 | | 28 |
| 100 | Survival of HIV-infected patients with compensated liver cirrhosis. <i>Aids</i> , 2010 , 24, 745-53 | 3.5 | 26 |
| 99 | Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfecting patients with prior nonresponse or relapse. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 53, 364-8 | 3.1 | 24 |
| 98 | Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. <i>Aids</i> , 2010 , 24, 1171-6 | 3.5 | 70 |
| 97 | Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010 , 24, 1064-6 | 3.5 | 103 |
| 96 | Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010 , 15, 881-6 | 1.6 | 28 |
| 95 | Viral hepatitis and HIV co-infection. <i>Antiviral Research</i> , 2010 , 85, 303-15 | 10.8 | 155 |
| 94 | Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy. <i>Journal of the International AIDS Society</i> , 2010 , 13, P208-P208 | 5.4 | 78 |
| 93 | Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice. <i>Journal of the International AIDS Society</i> , 2010 , 13, P35-P35 | 5.4 | 1 |
| 92 | The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 242-4 | 3.2 | |
| 91 | First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. <i>Journal of the International Association of Providers of AIDS Care</i> , 2009 , 8, 314-7 | | 6 |
| 90 | HIV protease inhibitors: recent clinical trials and recommendations on use. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1615-29 | 4 | 31 |
| 89 | Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1397-401 | 11.6 | 29 |
| 88 | Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. <i>Aids</i> , 2009 , 23, 689-96 | 3.5 | 218 |
| 87 | Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 790-5 | 3.4 | 31 |

| | | | |
|----|---|------|----|
| 86 | Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. <i>HIV Medicine</i> , 2009 , 10, 53-9 | 2.7 | 25 |
| 85 | Raltegravir and etravirine are active against HIV type 1 group O. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 225-7 | 1.6 | 39 |
| 84 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges?. <i>Journal of HIV Therapy</i> , 2009 , 14, 13-8 | | 10 |
| 83 | Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. <i>Antiviral Therapy</i> , 2009 , 14, 187-193 | 1.6 | 35 |
| 82 | Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 363-9 | 3.4 | 21 |
| 81 | Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 427-33 | 3.4 | 78 |
| 80 | Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2008 , 49, 916-22 | 13.4 | 36 |
| 79 | Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1365-73 | 5.1 | 48 |
| 78 | Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 699-704 | 5.1 | 61 |
| 77 | Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 626-7 | 5.1 | 15 |
| 76 | Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1782-5 | 11.6 | 16 |
| 75 | Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1470-2 | 5.1 | 16 |
| 74 | A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. <i>Aids</i> , 2008 , 22, 911-2 | 3.5 | 10 |
| 73 | Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients. <i>HIV Clinical Trials</i> , 2008 , 9, 440-4 | | 12 |
| 72 | Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 821-5 | 1.6 | 31 |
| 71 | Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 816-22 | 5.1 | 30 |
| 70 | Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. <i>Aids</i> , 2008 , 22, 2535-7 | 3.5 | 30 |
| 69 | Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 165-72 | 3.4 | 71 |

| | | | |
|----|---|-----|-----|
| 68 | Management of hepatitis B virus co-infection on and off antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2008 , 5, 86-93 | 5.9 | 7 |
| 67 | Emerging drugs for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2008 , 13, 1-19 | 3.7 | 39 |
| 66 | Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 200-5 | 5.1 | 58 |
| 65 | Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. <i>Antiviral Therapy</i> , 2008 , 13, 103-7 | 1.6 | 20 |
| 64 | Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. <i>Antiviral Therapy</i> , 2008 , 13, 429-37 | 1.6 | 27 |
| 63 | Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir. <i>Antiviral Therapy</i> , 2008 , 13, 429-438 | 1.6 | 46 |
| 62 | Distinct Hepatitis C virus Kinetics in HIV-Infected Patients Treated with Ribavirin plus Either Pegylated Interferon α or β . <i>Antiviral Therapy</i> , 2008 , 13, 511-517 | 1.6 | 5 |
| 61 | Antiretroviral-Associated Portal Hypertension: A New Clinical Condition? Prevalence, Predictors and Outcome. <i>Antiviral Therapy</i> , 2008 , 13, 103-108 | 1.6 | 56 |
| 60 | Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 387-91 | 3.4 | 29 |
| 59 | Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 392-5 | 3.4 | 15 |
| 58 | Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 1237-41 | 1.6 | 10 |
| 57 | Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. <i>Journal of Infectious Diseases</i> , 2007 , 195, 973-9 | 7 | 63 |
| 56 | Is natural conception a valid option for HIV-serodiscordant couples?. <i>Human Reproduction</i> , 2007 , 22, 2353-8 | 3.8 | 64 |
| 55 | Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007 , 21, 583-8 | 3.5 | 21 |
| 54 | Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 557-61 | 3.1 | 46 |
| 53 | Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. <i>Aids</i> , 2007 , 21, 41-6 | 3.5 | 108 |
| 52 | Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 972-82 | 1.6 | 156 |
| 51 | Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfecting patients with persistently normal transaminases. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 801-4 | 1.6 | 17 |

| | | | |
|----|--|------|-----|
| 50 | Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1181-3 | 7 | 38 |
| 49 | Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2007 , 196, 670-6 | 7 | 127 |
| 48 | Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 45, 439-44 | 3.1 | 38 |
| 47 | Outbreak of syphilis, but not of acute hepatitis C, among HIV-infected homosexual men in Madrid. <i>HIV Clinical Trials</i> , 2007 , 8, 98-101 | | 17 |
| 46 | Update on the treatment of chronic hepatitis C in HIV-infected patients. <i>AIDS Reviews</i> , 2007 , 9, 99-113 | 1.5 | 7 |
| 45 | Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin. <i>Antiviral Therapy</i> , 2007 , 12, 469-476 | 1.6 | 11 |
| 44 | Severe liver disease associated with prolonged exposure to antiretroviral drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 42, 177-82 | 3.1 | 126 |
| 43 | Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 43, 324-6 | 3.1 | 77 |
| 42 | Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. <i>HIV Clinical Trials</i> , 2006 , 7, 246-50 | | 21 |
| 41 | Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. <i>Clinical Infectious Diseases</i> , 2006 , 42, 291-5 | 11.6 | 104 |
| 40 | Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 806-9 | 5.1 | 28 |
| 39 | Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 842-8 | 1.6 | 53 |
| 38 | Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 333-7 | 1.6 | 19 |
| 37 | Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 825-9 | 1.6 | 22 |
| 36 | Management of chronic hepatitis B and C in HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 815-8 | 5.1 | 67 |
| 35 | Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1032-9 | 11.6 | 45 |
| 34 | Overview of the pharmacogenetics of HIV therapy. <i>Pharmacogenomics Journal</i> , 2006 , 6, 234-45 | 3.5 | 48 |
| 33 | Reproductive options for HIV-serodiscordant couples. <i>AIDS Reviews</i> , 2006 , 8, 158-70 | 1.5 | 20 |

| | | | |
|----|---|------|-----|
| 32 | Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. <i>Antiviral Therapy</i> , 2006 , 11, 869-77 | 1.6 | 9 |
| 31 | Sustained Virological Response following HCV Therapy is Associated with Non-Progression of Liver Fibrosis in HCV/HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2006 , 11, 869-878 | 1.6 | 30 |
| 30 | Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. <i>Clinical Infectious Diseases</i> , 2005 , 40, 1358-61 | 11.6 | 151 |
| 29 | Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 39, 401-5 | 3.1 | 67 |
| 28 | Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005 , 19, 569-75 | 3.5 | 62 |
| 27 | Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption. <i>Clinical Infectious Diseases</i> , 2005 , 41, 897-900 | 11.6 | 10 |
| 26 | Enfuvirtide is active against HIV type 1 group O. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 583-5 | 1.6 | 29 |
| 25 | Atazanavir: the advent of a new generation of more convenient protease inhibitors. <i>HIV Clinical Trials</i> , 2005 , 6, 50-61 | | 4 |
| 24 | Nucleoside/nucleotide backbones for the treatment of HIV infection. <i>Current Opinion in Investigational Drugs</i> , 2005 , 6, 812-22 | | 3 |
| 23 | Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 657-62 | 1.6 | 6 |
| 22 | Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 657-662 | 1.6 | 18 |
| 21 | Response to Interferon-Based Therapies in HIV-Infected Patients with Chronic Hepatitis C Due to Genotype 4. <i>Antiviral Therapy</i> , 2005 , 10, 167-170 | 1.6 | 8 |
| 20 | Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. <i>Clinical Infectious Diseases</i> , 2004 , 38, 430-2 | 11.6 | 108 |
| 19 | Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 2-17 | 3.4 | 46 |
| 18 | Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2004 , 9, 505-9 | 1.6 | 8 |
| 17 | Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. <i>Antiviral Therapy</i> , 2004 , 9, 987-92 | 1.6 | 9 |
| 16 | Combinations of nucleoside/nucleotide analogues for HIV therapy. <i>AIDS Reviews</i> , 2004 , 6, 234-43 | 1.5 | 15 |
| 15 | Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin. <i>Antiviral Therapy</i> , 2004 , 9, 505-509 | 1.6 | 21 |

| | | | |
|----|---|-----|-----|
| 14 | Long-Term Follow-Up of HIV-Infected Patients with Chronic Hepatitis C Virus Infection Treated with Interferon-Based Therapies. <i>Antiviral Therapy</i> , 2004 , 9, 987-992 | 1.6 | 38 |
| 13 | Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2003 , 17, 1023-8 | 3.5 | 143 |
| 12 | Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy. <i>HIV Clinical Trials</i> , 2003 , 4, 361-71 | | 16 |
| 11 | Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. <i>Aids</i> , 2002 , 16, 245-9 | 3.5 | 47 |
| 10 | SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. <i>HIV Clinical Trials</i> , 2002 , 3, 186-94 | | 54 |
| 9 | Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use. <i>AIDS Reviews</i> , 2002 , 4, 233-41 | 1.5 | 22 |
| 8 | Monthly cyclic therapy in heavily pretreated HIV-infected patients. <i>AIDS Patient Care and STDs</i> , 2001 , 15, 177-9 | 5.8 | |
| 7 | Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. <i>Aids</i> , 2000 , 14, 2153-7 | 3.5 | 63 |
| 6 | Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2000 , 14, 383-6 | 3.5 | 92 |
| 5 | Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. <i>Aids</i> , 2000 , 14, 807-12 | 3.5 | 109 |
| 4 | Is there a role for indinavir twice-daily in clinical practice?. <i>Clinical Microbiology and Infection</i> , 2000 , 6, 152-4 | 9.5 | 1 |
| 3 | Induction-maintenance (5 --> 3 drugs) in HIV-infected patients with high viral load. <i>AIDS Patient Care and STDs</i> , 2000 , 14, 573-4 | 5.8 | 3 |
| 2 | Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?. <i>Aids</i> , 2000 , 14, 1672-3 | 3.5 | 18 |
| 1 | Human Immunodeficiency Virus and the Liver974-987 | | 0 |